Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Licong Liang

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
BMC Cancer|February 5, 2025
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trialXiaoyang Hong, Yongjian Guo, Wenbo Shi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 20, 2023
Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinomaLulu Xie, Mingyu Liu, Mingyue Cai, et al.
Cell Death & Disease|January 13, 2023
Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastasesMingyu Liu, Lulu Xie, Yuying Zhang, et al.
Immunotargets and Therapy|November 3, 2025
Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II StudyLicong Liang, Jingwen Zhou, Jingjun Huang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 10, 2025
Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinomaYue Li, Xiaobin Wang, Feilong Ye, et al.
Cellular and Molecular Gastroenterology and Hepatology|July 22, 2024
Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal HypertensionRui Li, Zhile Liu, Wensou Huang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2020
Nanodrug with ROS and pH Dual-Sensitivity Ameliorates Liver Fibrosis via Multicellular RegulationLiteng Lin, Hengye Gong, Rui Li, et al.
International Journal of Surgery (London, England)|December 17, 2025
SIRT or TACE in combination with Lenvatinib and PD-(L)1 inhibitor in high tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched studyJingjun Huang, Huimin Niu, Hui Zhang, et al.
International Journal of Surgery (London, England)|June 13, 2024
Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort studyMingyue Cai, Licong Liang, Jian Zhang, et al.
The New England Journal of Medicine|June 10, 2026
Subretinal Gene Therapy for X-Linked RetinoschisisLicong Liang, Kaiqin She, Chengda Ren, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
BMC Cancer|February 5, 2025
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trialXiaoyang Hong, Yongjian Guo, Wenbo Shi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 20, 2023
Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinomaLulu Xie, Mingyu Liu, Mingyue Cai, et al.
Cell Death & Disease|January 13, 2023
Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastasesMingyu Liu, Lulu Xie, Yuying Zhang, et al.
Immunotargets and Therapy|November 3, 2025
Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II StudyLicong Liang, Jingwen Zhou, Jingjun Huang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 10, 2025
Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinomaYue Li, Xiaobin Wang, Feilong Ye, et al.
Cellular and Molecular Gastroenterology and Hepatology|July 22, 2024
Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal HypertensionRui Li, Zhile Liu, Wensou Huang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2020
Nanodrug with ROS and pH Dual-Sensitivity Ameliorates Liver Fibrosis via Multicellular RegulationLiteng Lin, Hengye Gong, Rui Li, et al.
International Journal of Surgery (London, England)|December 17, 2025
SIRT or TACE in combination with Lenvatinib and PD-(L)1 inhibitor in high tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched studyJingjun Huang, Huimin Niu, Hui Zhang, et al.
International Journal of Surgery (London, England)|June 13, 2024
Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort studyMingyue Cai, Licong Liang, Jian Zhang, et al.
The New England Journal of Medicine|June 10, 2026
Subretinal Gene Therapy for X-Linked RetinoschisisLicong Liang, Kaiqin She, Chengda Ren, et al.
Pageof 4